scholarly journals One-Hour Oral Glucose Tolerance Tests for the Prediction and Diagnostic Surveillance of Type 1 Diabetes

2020 ◽  
Vol 105 (11) ◽  
Author(s):  
Kimber M Simmons ◽  
Jay M Sosenko ◽  
Megan Warnock ◽  
Susan Geyer ◽  
Heba M Ismail ◽  
...  

Abstract Context Once islet autoantibody–positive individuals are identified, predicting which individuals are at highest risk for type 1 diabetes (T1D) is important. A metabolic risk score derived from 2-hour oral glucose tolerance test (OGTT) data, the Diabetes Prevention Trial-Type 1 risk score (DPTRS), can accurately predict T1D. However, 2-hour OGTTs are time-consuming and costly. Objective We aimed to determine whether a risk score derived from 1-hour OGTT data can predict T1D as accurately as the DPTRS. Secondarily, we evaluated whether a 1-hour glucose value can be used for diagnostic surveillance. Methods The DPTRS was modified to derive a 1-hour OGTT risk score (DPTRS60) using fasting C-peptide, 1-hour glucose and C-peptide, age, and body mass index. Areas under receiver operating curves (ROCAUCs) were used to compare prediction accuracies of DPTRS60 with DPTRS in Diabetes Prevention Trial–Type 1 (DPT-1) (n = 654) and TrialNet Pathway to Prevention (TNPTP) (n = 4610) participants. Negative predictive values (NPV) for T1D diagnosis were derived for 1-hour glucose thresholds. Results ROCAUCs for T1D prediction 5 years from baseline were similar between DPTRS60 and DPTRS (DPT-1: 0.805 and 0.794; TNPTP: 0.832 and 0.847, respectively). DPTRS60 predicted T1D significantly better than 2-hour glucose (P < .001 in both cohorts). A 1-hour glucose of less than 180 mg/dL had a similar NPV, positive predictive value, and specificity for T1D development before the next 6-month visit as the standard 2-hour threshold of less than 140 mg/dL (both ≥ 98.5%). Conclusion A 1-hour OGTT can predict T1D as accurately as a 2-hour OGTT with minimal risk of missing a T1D diagnosis before the next visit.

Diabetes Care ◽  
2009 ◽  
Vol 33 (3) ◽  
pp. 620-625 ◽  
Author(s):  
J. M. Sosenko ◽  
J. P. Palmer ◽  
L. E. Rafkin ◽  
J. P. Krischer ◽  
D. Cuthbertson ◽  
...  

2021 ◽  
Author(s):  
Michael G Voss ◽  
David D Cuthbertson ◽  
Mario M Cleves ◽  
Ping Xu ◽  
Carmella Evans-Molina ◽  
...  

<b>Objective:</b> To assess the progression of type 1 diabetes using time to peak glucose or C-peptide during oral glucose tolerance tests (OGTTs) in autoantibody positive (Ab+) relatives of people with type 1 diabetes. <p><b>Methods:</b> We examined 2-hour OGTTs of participants in the Diabetes Prevention Trial Type 1 (DPT-1) and TrialNet Pathway to Prevention (PTP) studies. We included 706 DPT-1 participants (Mean±SD age: 13.84±9.53 years; BMI-Z-Score: 0.33±1.07; 56.1% male) and 3,720 PTP participants (age: 16.01±12.33 Years, BMI-Z-Score 0.66±1.3; 49.7% male). Log-rank testing and Cox regression analyses with adjustments (age, sex, race, BMI Z-Score, HOMA-IR and peak Glucose/C-peptide levels, respectively) were performed. </p> <p><b>Results:</b> In each of DPT-1 and PTP, higher 5-year diabetes progression risk was seen in those with time to peak glucose >30 min and time to peak C-peptide >60 min (p<0.001 for all groups), before and after adjustments. In models examining strength of association with diabetes development, associations were greater for time to peak C-peptide versus peak C-peptide value (DPT-1: X<sup>2 </sup>= 25.76 vs. X<sup>2</sup> = 8.62 and PTP: X<sup>2 </sup>= 149.19 vs. X<sup>2</sup> = 79.98; all p<0.001). Changes in the percentage of individuals with delayed glucose and/or C-peptide peaks were noted over time.</p> <p><b>Conclusions: </b>In two independent at risk populations, we show that those with delayed OGTT peak times for glucose or C-peptide are at higher risk of diabetes development within 5 years, independent of peak levels. Moreover, time to peak C-peptide appears more predictive than the peak level, suggesting its potential use as a specific biomarker for diabetes progression. </p>


Diabetes Care ◽  
2008 ◽  
Vol 31 (11) ◽  
pp. 2188-2192 ◽  
Author(s):  
J. M. Sosenko ◽  
J. P. Palmer ◽  
L. Rafkin-Mervis ◽  
J. P. Krischer ◽  
D. Cuthbertson ◽  
...  

2019 ◽  
Vol 20 (4) ◽  
pp. 408-413
Author(s):  
Heba M. Ismail ◽  
Carmella Evans‐Molina ◽  
Linda A. DiMeglio ◽  
Dorothy J. Becker ◽  
Ingrid Libman ◽  
...  

Diabetes Care ◽  
2007 ◽  
Vol 31 (3) ◽  
pp. 528-533 ◽  
Author(s):  
J. M. Sosenko ◽  
J. P. Krischer ◽  
J. P. Palmer ◽  
J. Mahon ◽  
C. Cowie ◽  
...  

Diabetes Care ◽  
2014 ◽  
Vol 37 (4) ◽  
pp. 979-984 ◽  
Author(s):  
Jay M. Sosenko ◽  
Jay S. Skyler ◽  
Jeffrey Mahon ◽  
Jeffrey P. Krischer ◽  
Carla J. Greenbaum ◽  
...  

Diabetes Care ◽  
2012 ◽  
Vol 35 (7) ◽  
pp. 1552-1555 ◽  
Author(s):  
J. M. Sosenko ◽  
J. S. Skyler ◽  
J. Mahon ◽  
J. P. Krischer ◽  
C. A. Beam ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document